Newsroom

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company’s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of pati...

EL PASO, Texas--(BUSINESS WIRE)--ReDiscover Television, a 100GROUP client, and CLO Prods proudly announce the world premiere of BirdDog, a gripping new indie drama-thriller series created and written by Christine Lozano. Filmed entirely in the vibrant border city of El Paso, Texas, BirdDog stars Jessica Jimenez, Nichole Hamilton, Talia Leilani, Adam Zarowski, Russell Elleby and Xavier Felix as a ragtag crew of FBI rejects recruited into BirdDog Unit under CISA, Cybersecurity and Infrastructure...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE:ARDT) securities during the period of July 18, 2024 through November 12, 2025, inclusive (“the Class Period”). If you suffered a loss on your Ardent investments, you have until March 9, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS]...

LOS ANGELES--(BUSINESS WIRE)--FRMI Investors Have Opportunity to Lead Fermi Inc. Securities Fraud Lawsuit with the Schall Law Firm...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025. Skye is a clinical stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Skye Bioscience, Inc. (NASDAQ: SKYE) Misled Investors Regarding its Business Ope...

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Firefly Aerospace Inc. (“Firefly”) (NASDAQ: FLY) on behalf of those who purchased or otherwise acquired Firefly: (1) common stock pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with the company’s IPO conducted on or about August 7, 2025; an...

PECHINO, ALAMEDA, Calif. e TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) e Acepodia (6976:TT), oggi hanno annunciato la firma di un accordo di opzione e licenza finalizzato a permettere la valutazione strutturata di programmi coniugati farmaco-anticorpo bispecifico (BsADC) per promuovere ulteriormente lo sviluppo di coniugati farmaco-anticorpo bispecifico con doppio payload (BsAD2Cs). L'accordo accorda ad Acepodia un'opzio...

BEIJING et ALAMEDA, Californie et TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE : 688796 ; HKEX : 02315) et Acepodia (6976 : TT) ont annoncé aujourd'hui que les entreprises ont conclu un accord d'option et de licence destiné à permettre l'évaluation structurée des programmes de conjugués anticorps-médicament bispécifiques (BsADC) afin de faire progresser le développement de conjugués anticorps-médicament bispécifiques à double charge utile (BsA...

PEKÍN y ALAMEDA, California, y TAIPÉI, Taiwán--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) y Acepodia (6976:TT) anunciaron hoy la firma de un contrato de opción y licencia con el objetivo de establecer un marco para la evaluación estructurada de programas de conjugados anticuerpo-fármaco biespecíficos (BsADC) y seguir avanzando en el desarrollo de conjugados anticuerpo-fármaco biespecíficos de carga dual (BsAD2C). El acuerdo otorga a Ac...

BEIJING & ALAMEDA, Calif. & TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) en Acepodia (6976:TT) hebben vandaag bekendgemaakt dat zij een optie- en licentieovereenkomst hebben gesloten om een gestructureerde evaluatie van bispecifieke antilichaam-geneesmiddelconjugaatprogramma's (BsADC) mogelijk te maken. Hiermee beogen ze de ontwikkeling van bispecifieke antilichaam-geneesmiddelconjugaten met dubbele lading (BsAD2C's) verd...